This bridging replaces factor VIII, restoring thrombin production and clotting ability. The open-label, 2-part phase 3 FRONTIER3 trial (ClinicalTrials.gov Identifier: NCT05306418), evaluated the ...

Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

Cerebral venous thrombosis is a rare but potentially life-threatening condition that is particularly prevalent in young women (ie, mean age 44 years) and accounts for 0·5–3% of all strokes. The ...

Atryn, which inhibits the activity of the coagulation proteins Thrombin, factor Xa and factor IXa ... Biomedical's Ixiaro (Japanese encephalitis SA14-4-2 virus vaccine) was approved for the ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...

2 3 Against this background ... Moreover, measuring DOAC levels involves assays (dilute thrombin time for dabigatran, DOAC-calibrated anti-Xa levels for oral factor Xa inhibitors) that are not ...

Oncotelic Therapeutics, a leader in RNA-based therapeutics, is pleased to announce that Vuong Trieu, Ph.D., Chairman & CEO, will be delivering a featured presentation at the SWCR 2025 Conference on ...